Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYCCNASDAQ:INNTNASDAQ:ITRMOTCMKTS:NEVPFNASDAQ:OHRP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$1.60-30.4%$2.31$1.41▼$13.20$2.11M0.54176,310 shs3.47 million shsINNTInnovate Biopharmaceuticals$0.97$0.37▼$1.67$8K-0.39525,982 shsN/AITRMIterum Therapeutics$1.57+1.3%$1.51$0.62▼$2.50$25.80M2.36501,690 shs50,845 shsNEVPFAbliva AB (publ)$0.01$0.01$0.01▼$0.02N/AN/AN/AN/AOHRPOHR Pharmaceutical$0.44+4.7%$7.37$1.60▼$6.28$1.25M0.84180,228 shs25,441 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals-29.82%-13.51%-17.95%-24.53%-82.25%INNTInnovate Biopharmaceuticals0.00%0.00%0.00%0.00%-99.89%ITRMIterum Therapeutics+1.29%+9.79%+0.64%-8.72%+57.00%NEVPFAbliva AB (publ)0.00%0.00%0.00%-50.00%0.00%OHRPOHR Pharmaceutical0.00%+0.26%-12.07%-32.12%+220.64%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCCCyclacel Pharmaceuticals1.0079 of 5 stars3.33.00.00.00.60.00.6INNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics1.2106 of 5 stars3.53.00.00.00.60.00.6NEVPFAbliva AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCCCyclacel Pharmaceuticals2.50Moderate Buy$21.001,212.50% UpsideINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AITRMIterum Therapeutics3.00Buy$6.00282.17% UpsideNEVPFAbliva AB (publ)N/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/ACurrent Analyst RatingsLatest CYCC, INNT, OHRP, NEVPF, and ITRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCCCyclacel Pharmaceuticals$420K5.03N/AN/A$0.57 per share2.81INNTInnovate BiopharmaceuticalsN/AN/AN/AN/A($0.27) per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.48) per shareN/ANEVPFAbliva AB (publ)N/AN/AN/AN/A$0.04 per shareN/AOHRPOHR PharmaceuticalN/AN/AN/AN/A$3.86 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCCCyclacel Pharmaceuticals-$22.56M-$27.22N/AN/AN/AN/A-448.19%-151.29%5/9/2024 (Estimated)INNTInnovate Biopharmaceuticals-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/AITRMIterum Therapeutics-$38.37M-$2.97N/AN/AN/AN/A-664.00%-87.64%5/10/2024 (Estimated)NEVPFAbliva AB (publ)-$8.45MN/A0.00∞N/AN/A-63.75%-57.93%N/AOHRPOHR Pharmaceutical-$13.23MN/A0.00∞N/AN/A-75.46%-71.18%N/ALatest CYCC, INNT, OHRP, NEVPF, and ITRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ITRMIterum Therapeutics-$1.02-$0.94+$0.08-$0.94N/AN/A3/19/2024Q4 2023CYCCCyclacel Pharmaceuticals-$6.35-$6.23+$0.12-$6.23N/A$0.03 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCCCyclacel PharmaceuticalsN/A0.910.91INNTInnovate BiopharmaceuticalsN/A0.350.35ITRMIterum Therapeutics3.631.891.89NEVPFAbliva AB (publ)N/A6.606.60OHRPOHR PharmaceuticalN/A3.733.73OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCCCyclacel Pharmaceuticals23.58%INNTInnovate Biopharmaceuticals5.88%ITRMIterum Therapeutics9.21%NEVPFAbliva AB (publ)N/AOHRPOHR Pharmaceutical10.70%Insider OwnershipCompanyInsider OwnershipCYCCCyclacel Pharmaceuticals8.47%INNTInnovate Biopharmaceuticals7.90%ITRMIterum Therapeutics5.40%NEVPFAbliva AB (publ)N/AOHRPOHR Pharmaceutical12.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYCCCyclacel Pharmaceuticals2,0181.32 million1.21 millionOptionableINNTInnovate Biopharmaceuticals841.33 millionN/ANot OptionableITRMIterum Therapeutics1416.43 million15.54 millionNot OptionableNEVPFAbliva AB (publ)8N/AN/ANot OptionableOHRPOHR Pharmaceutical32.83 millionN/ANot OptionableCYCC, INNT, OHRP, NEVPF, and ITRM HeadlinesSourceHeadlinePharmaceutical Stocksbenzinga.com - April 14 at 8:00 AMCYCC Cyclacel Pharmaceuticals, Inc.seekingalpha.com - March 17 at 4:20 PMSun Pharmaceutical Industries Ltd.moneycontrol.com - February 3 at 8:52 AMAI Advances Pharmaceutical Packaging Inspectiondesignnews.com - May 22 at 9:22 AMThe OHRP and SUPPORT — Another Viewnejm.org - April 21 at 3:16 PMWorking at the Smithsoniansi.edu - February 23 at 5:49 PMOHR Pharmaceutical (OHRP) is now in Oversold Territoryca.finance.yahoo.com - September 12 at 11:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCyclacel PharmaceuticalsNASDAQ:CYCCCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Innovate BiopharmaceuticalsNASDAQ:INNTInnovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Abliva AB (publ)OTCMKTS:NEVPFAbliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.OHR PharmaceuticalNASDAQ:OHRPOHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.